1. Scrip
  2. >>Business

PDC Promises: Japanese Startup Fills Pharma’s Pipelines With Peptide-Drug Conjugates

 
• By Brian Yang

Originated from Tokyo University, drug discovery firm PeptiDream recently competes pre-clinical study for its anti-flu peptide PD-001, after signing 17 deals with large drug makers in 11 years. The company's CEO Patrick Reid outlines to Scrip prospects of peptide-drug conjugates (PDCs) and discovery strategy.

operator

Kanagawa, Japan-based biotech startup PeptiDream Inc. has signed licensing deals with many multinational drug makers, 17 in total in 11 years, courting Roche's Genentech, Janssen Pharmaceuticals Inc. and Shionogi & Co. Ltd., among others.

The key to this track record is its proprietary Peptide Discovery Platform System (PDPS) platform, in particular, peptide-drug conjugates (PDCs),...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

More from Business

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.